SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Mixed oncology-trial results are driving attention: traders cite BioNTechs BNT113 setback and modest breast-cancer benefit, while bulls point to other promising pipeline readouts and upcoming updates. Debate also reflects concern over the leadership transition and the time needed to turn the pipeline into commercial products.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and lifted its full-year outlook, but a softer next-quarter organic growth forecast signaled deceleration and drove a sharp selloff. Traders are debating whether slowing messaging growth and weaker customer expansion outweigh the strong results, while some see the pullback as a potential bounce opportunity.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as traders discuss a shift from volatile technology and growth stocks toward dividend-paying value and defensive holdings amid market uncertainty. Many point to its recent strength and keep accumulating, while others question its yield and warn that rising Treasury yields or a return to tech could weigh on the fund.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Traders are focused on whether Q3 results will show that oral Wegovy demand and international expansion can offset concerns about Eli Lillys competitive lead in GLP-1 drugs. The community is divided: some see the pill rollout and low valuation as recovery potential, while others remain cautious about Novos execution, management and pipeline; the Hengrui licensing deal also drew debate as a longer-term pipeline move.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a fresh 52-week high has put TGTX in focus, with traders pointing to BRIUMVIs commercial growth and anticipation of earnings and upcoming subcutaneous data. Buyout and short-squeeze theories are circulating, but remain speculation; others see the rally as momentum ahead of those catalysts.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report, with record sales and revenue growth but an EPS miss and weaker margins, sparked a sharp rally and renewed short-squeeze speculation; traders are also citing the SECs decision to close its investigation without recommending enforcement. The move has drawn competing views, with bulls focused on growth and squeeze potential while bears question profitability, guidance and valuation.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff and persistent volatility dominate discussion, with traders pointing to broader weakness in miners and uncertainty over Sangdongs production ramp and near-term cash flows. Some remain bullish on tungsten-market fundamentals and the mines first shipment, while others say the investor-day discussion offered little new detail and are concerned about execution.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings, supported by growth in Dupixent and Eylea HD, sparked a sharp share-price surge and a new 52-week high. Traders are broadly bullish on the breakout, while debating whether the move can hold or will retrace.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access at least 80,000 U.S. cell sites, including Crown Castles towers, have focused attention on the prospect of a major new leasing customer. Traders see potential tower revenue upside, while skeptics note that no agreement is signed and question whether SpaceXs wireless plans will translate into meaningful demand.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A steep selloff in Aehr shares is driving discussion as traders debate whether broader AI and semiconductor weakness, valuation concerns and bearish options flow point to more downside or an oversold setup ahead of earnings. Bulls are watching guidance, backlog and potential AI test-system orders, while skeptics question execution and the companys ability to justify its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) delivered earnings and revenue surprises of +7.69% and +1.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

STAAR Surgical Company (STAAR or the Company) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Mr...

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STAAR Surgical to Participate in Upcoming Investor Conferences

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced that Warren Foust, President and Chief Executive Officer, and Deborah Andrews, Executive Vice President and Chief Financial...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA) SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation...

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced that it will release financial results and a letter to shareholders for the third quarter ended October 2, 2026, on Wednesday...

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

STAAR Surgical Company (STAAR or the Company) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report...

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA). SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation...

STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent...

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Staar Surgical Co.

STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Wedbush said the recovery in China may prompt a valuation re-rating of the stock and multiple expansion to historical levels.</li><li>Canaccord stated that even though it updated its model for Staar Surgical, the company provided very little information compared to its April preannouncement.</li><li>The company reported first-quarter net sales of $93.5 million, beating Wall Street expectations of $78.72 million</li></ul>&nbsp;Shares of Staar Surgical (STAA) shot up more than 10% on Thursday after multiple analysts turned bullish on the stock following strong quarterly results.Wedbush updated Staar Surgical to ‘Outperform’ from a ‘Neutral’ rating and hiked its price target to $40 from $26,&nbsp;representing a 53% hike from the firm's previous estimate.<h2 class="st-heading-2">Wedbush Says STAA Has Potential To Exceed Its Bull Case Scenario</h2>Wedbush stated that Staar Surgical’s first-quarter earnings report indicates the company is either at or nearing the inflection point for a full recovery in China, according to TheFly.The firm also stated that it has taken a long-term bet on the company, as Staar Surgical has the potential to exceed its bull-case scenario in the upcoming quarters, and it would prefer to be early rather than late on Staar Surgical’s growth story.&nbsp;&nbsp;It added that the recovery in China may prompt a valuation re-rating of the stock and multiple expansion to historical levels.Meanwhile, Canaccord increased Staar Surgical’s price target to $32 from $27 and kept a ‘Buy’ rating. The firm noted that the quarterly report provides a strong foundation for the remainder of 2026. However, Canaccord stated that even though it updated its model for the stock, the company provided very little information compared to its April preannouncement.&nbsp;Adam Maeder, analyst at Pipe Sandler, raised the company stock price target to $33 from $16. Maeder noted that Staar Surgical’s Chinese business was impressive. He added that the company’s first-quarter results were in line with its preannouncement in April; however, despite a good start to the year, the company did not provide full-year guidance or add more information on the second-quarter outlook.<h2 class="st-heading-2">Staar Surgical’s Q1 Earnings Report</h2>The company reported first-quarter net sales of $93.5 million, beating Wall Street expectations of $78.72 million, while earnings stood at $0.10 per share compared to a loss of $1.10 per share in the year-ago quarter.Regarding its China business, the company stated that net sales in China were mainly driven by a recovery in in-market demand, positioning it better for the second quarter and the rest of the year.<h2 class="st-heading-2">What Retail Thinks About STAA Stock</h2>On Stocktwits, retail sentiment surrounding the stock has improved to ‘extremely bullish’ from ‘bullish’, while message volume improved to ‘extremely high’ from ‘normal’ in the past 24 hours.Shares of Staar Surgical have gained more than 38% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-elon-musk-pay-package-share-registration-what-it-means/cZBNYDmReP3">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/amd-lisa-su-ai-agents-driving-tremendous-demand-amd-stock-q1-earnings/cZQzIIAReO5">AMD's Lisa Su Says AI Agents Are Driving ‘Tremendous Demand’, Touts Chipmaker's Portfolio Amid Blowout Q1</a>

In this photo illustration, the Staar Surgical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wedbush stated that Staar Surgical could be at or near an inflection point for a full China rebound, according to TheFly. 

STAA Stock On Track For Its Fourth Straight Session Of Gains –  This Analyst Would Rather Be Early Than Late On Staar’s Growth Story

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$24.54
Prev Close	$25.24
Open	$25.00
Dividend Yield	0.00%
50-Day Moving Average	$22.42
Beta	0.79
Avg. Volume	1.16M
PE Ratio	369.02

52-Week High	$35.87
52-Week Low	$15.59
Market Capitalization	$1.23B
EPS (Annual)	-$1.62
Price to Book	3.37
Revenue Per Employee	$250,200.63

Feed

News

Sentiment

Earnings

Fundamentals

Info

STAA Fundamentals